Evidence map›Paper›PMID 40712793›Full record

ArticleUrology2025

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma.

Lauren Loebach, Braden Millan, Maria Antony, Julie Solomon, Christopher Ricketts, Christopher Koller, Milan H Patel, Ruben Blachman-Braun, Sandeep Gurram, Cathy Vocke and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lauren LoebachUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Braden MillanUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Maria AntonyUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Julie SolomonUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Christopher RickettsUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Christopher KollerUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Milan H PatelUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Ruben Blachman-BraunUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Sandeep GurramUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Cathy VockeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Maria J MerinoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
W Marston LinehanUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mark W BallUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: mark.ball@nih.gov.

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

objectiveTo evaluate the proportion of von Hippel-Lindau (VHL) patients with high-grade disease and analyze the association of clinical, pathologic, and genetic factors with high-grade disease.

methodsClear cell renal cell carcinoma (ccRCC) specimens resected from VHL patients between 2006 and 2021 at the National Cancer Institute were evaluated. Pathologic, demographic, and genetic data were obtained from clinical records. Multivariate logistic regression models analyzed the association between pathologic grade and demographic information, tumor size, history of previous ipsilateral partial nephrectomy (PN), and germline VHL gene variant.

resultsFrom 229 patients with VHL, we identified 2555 ccRCC tumor specimens, of which 203 (7.94%) tumors were high-grade. Over the whole study period, 99 (43.2%) patients developed a high-grade tumor. Older age (odds ratio (OR) 1.02, P<.0001) and increasing tumor size (OR 1.58, P<.0001) were associated with high-grade pathology. Prior ipsilateral PN (OR 2.10, P=.002) and germline frameshift VHL variants (OR 2.38, P=.01) were also associated with high-grade pathology.

conclusionThese results demonstrate a strong association between tumor size, age at surgery, re-operative surgery status, and VHL frameshift genetic variant and high-grade pathology in VHL-associated RCC. These factors can be used clinically to assist in surgical intervention decision-making.

Indexed as

Carcinoma, Renal CellKidney Neoplasmsvon Hippel-Lindau DiseaseAdultAgedFemaleGerm-Line MutationHumansMaleMiddle AgedNeoplasm GradingNephrectomyRetrospective StudiesVon Hippel-Lindau Tumor Suppressor ProteinVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID40712793
PMCPMC12421646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.